Empagliflozine wordt voornamelijk gemetaboliseerd door UGT-enzymen combinatie met UGT-inducerende middelen (zoals rifampicine of fenytoïne) ontraden, omdat de werkzaamheid van empagliflozine mogelijk afneemt. Indien de combinatie toch noodzakelijk is, de respons op empagliflozine beoordelen middels controle van de bloedglucoseregulatie.
9/17/2019 · The Empagliflozin Outcome Trial in patients with Chronic Heart Failure with Reduced Ejection Fraction (EMPEROR-REDUCED) and the Empagliflozin Outcome Trial in patients with Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-PRESERVED), are double-blinded phase III randomized clinical trials evaluating the efficacy and safety of empagliflozin 10mg compared to placebo in chronic HF patients. EMPERIAL-REDUCED and EMPERIAL-PRESERVED trials will study the effect of empagliflozin .
5/9/2017 · Inspired by animal studies showing effect of a sodium-glucose cotransporter-2 (SGLT-2) inhibitor ( empagliflozin ) on oxidative stress and a recent trial evaluating empagliflozin that demonstrated improved cardiovascular outcomes in patients with T2D at high risk of cardiovascular events, we hypothesise that empagliflozin lowers oxidative stress.
1/9/2021 · Empagliflozin reduced the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS tertiles [hazard ratio (HR) 0.83 (0.68–1.02), HR 0.74 (0.58–0.94), and HR 0.61 (0.46–0.82) for Empagliflozin improved KCCQ-CSS, total symptom score, and overall summary score at 3,.
1/12/2018 · The FPG concentration (the mean of four determinations performed on days 5, 4, 2, and 1 before the start of empagliflozin ) was 195 ± 9 mg/dL this decreased to 169 ± 11 mg/dL (difference from baseline mean, 25 ± 6 mg/dL) and to 165 ± 7 mg/dL (difference from baseline mean, 29 ± 6 mg/dL) at 24 hours and 48 hours after starting empagliflozin (both P < 0.001).3/1/2019 · Empagliflozin , an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats | Journal of Pharmacology and Experimental Therapeutics. Research Article Cardiovascular.9/29/2020 · Suara.com - Obat antidiabetes golongan SGLT2 -- Empagliflozin , dipercaya memiliki manfaat bukan hanya untuk menurunkan kadar gula darah dalam tubuh tetapi juga juga memberikan efek perbaikan pada pasien gagal jantung.Empagliflozin related Ertugliflozin Evogliptin related Fasiglifam Gemigliptin related Glimepiride related GSK-2330672 Ipragliflozin related Lacosamide Linagliptin related Lobeglitazone Luseogliflozin related Melogliptin Miglitol related More >> Blood Products Anagrelide related Apixaban related Ataciguat related Avatrombopag related Avoralstat Azacitidine, Diabetes mellitus type 2. Volwassenen. 10 mg 1×/dag. Bij gebruik in combinatie met insuline of een middel dat de insuline-afgifte bevordert (zoals een sulfonylureumderivaat): overweeg een lagere dosis insuline of insuline-afgiftebevorderend middel te geven, om de kans op hypoglykemie te verminderen.
12/4/2020 · Mod: dr. Zunilda Dj. Sadikin, MS, Sp. FK – New perspectives on recent cardiovascular outcome trial focus on Empagliflozin Prof. Dra. Arini Setiawati, Ph.D – Cost-effectiveness of Empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk Prof. Dr. Dra. Erna Kristin, Apt, M.Si – Discussion: 11.40-13.00: Break
